{"protocolSection":{"identificationModule":{"nctId":"NCT00216749","orgStudyIdInfo":{"id":"Korea Pletaal CSPS PMS"},"organization":{"fullName":"Korea Otsuka Pharmaceutical Co., Ltd.","class":"INDUSTRY"},"briefTitle":"Efficacy and Safety of Cilostazol for the Indication of CSPS","officialTitle":"Post Marketing Surveillance of Efficacy and Safety of Cilostazol for the Indication of CSPS"},"statusModule":{"statusVerifiedDate":"2009-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2003-12"},"primaryCompletionDateStruct":{"date":"2007-10","type":"ACTUAL"},"completionDateStruct":{"date":"2007-10","type":"ACTUAL"},"studyFirstSubmitDate":"2005-09-14","studyFirstSubmitQcDate":"2005-09-14","studyFirstPostDateStruct":{"date":"2005-09-22","type":"ESTIMATED"},"lastUpdateSubmitDate":"2009-12-15","lastUpdatePostDateStruct":{"date":"2009-12-17","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Clinical Reserch Team Leader","oldOrganization":"Korea Otsuka Pharmaceutical Co. Ltd"},"leadSponsor":{"name":"Korea Otsuka Pharmaceutical Co., Ltd.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This is a multicenter, open-label, prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction.","detailedDescription":"This is a multicenter, open-label, prospective study of cilostazol use to prevention of recurrence in patients with cerebral infarction.\n\nQualified patients will be treated with cilostazol by physician's assessment. This study will be continued for 4 years. More than 600 patients for 4 years."},"conditionsModule":{"conditions":["Cerebral Infarction"],"keywords":["Cerebral Infarction Prevention","Cilostazol"]},"designModule":{"studyType":"OBSERVATIONAL","designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":650,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cilostazol","description":"Cilostazol Treatment Patients who were in stable states after the occurrence of cerebral infarction (except cardiogenic cerebral embolism)"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"1)Efficacy:Recurrence of cerebral infarction 2)Safety:Adverse Event","timeFrame":"3M"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient with an experience of cerebral infarction and having a purpose for prevention of recurrence of cerebral infarction.\n* Age: more than 18 years of age\n\nExclusion Criteria:\n\n* Unqualified patients judged by study investigator(s)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients in restabilization status after cerebral infarction (excluding cardiogenic cerebral embolism)","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Bo Youn Seo","affiliation":"Korea Otsuka Pharmaceutical Co., Ltd.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Asan Medical Center","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007238","term":"Infarction"}],"ancestors":[{"id":"D000007511","term":"Ischemia"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000009336","term":"Necrosis"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000020521","term":"Stroke"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M9972","name":"Infarction","asFound":"Infarction","relevance":"HIGH"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Cerebral Infarction","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M1788","name":"Cilostazol","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"},{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"Resp","name":"Respiratory System Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}